Tetrahydrocannabivarin (THCV)

Tetrahydrocannabivarin (THCV), the propyl-chain structural homolog of delta-9-tetrahydrocannabinol (THC), is a naturally occurring phytocannabinoid first identified in Cannabis sativa by Merkus in 1971 and subsequently characterized as pharmacologically distinct from THC through a series of receptor binding, functional, and behavioral studies spanning more than three decades. The compound differs from THC by a single structural modification: the replacement of the pentyl (five-carbon) alkyl side chain at the C-3 position of the dibenzopyran ring with a propyl (three-carbon) chain, a change that profoundly alters its receptor pharmacology. At the cannabinoid CB1 receptor, THCV acts as a neutral antagonist at low concentrations (KB approximately 85 to 93 nM in GTPgammaS assays) and as a weak partial agonist at higher concentrations, a dose-dependent profile first formally characterized by Thomas et al. (2005) and confirmed in vivo by Pertwee et al. (2007) in mouse behavioral models [1, 2]. At the CB2 receptor, THCV acts as a partial agonist. The neutral antagonist character at CB1 is the pharmacological feature of greatest translational interest, distinguishing THCV from the CB1 inverse agonists rimonabant and taranabant, both of which were withdrawn or discontinued owing to psychiatric adverse events attributed to inverse agonist-driven suppression of constitutive CB1 signaling.

Beyond the endocannabinoid system, THCV engages multiple additional molecular targets: it activates GPR55, the putative cannabinoid receptor implicated in metabolic regulation and bone physiology; it activates 5-HT1A serotonin receptors, producing antipsychotic-like effects in preclinical models; it modulates transient receptor potential channels including TRPV2 activation and TRPV6 inhibition; and it suppresses arachidonic acid-induced lipogenesis in human sebocytes through mechanisms that remain incompletely characterized [3, 4, 5, 6]. This multi-target pharmacology supports the diverse preclinical and early clinical activity reported for the compound across metabolic, neurodegenerative, anti-inflammatory, and dermatologic research domains.

The metabolic application has produced the most advanced clinical evidence. Wargent et al. (2013) demonstrated that THCV dose-dependently ameliorates insulin sensitivity and glucose tolerance in dietary-induced obese and genetically obese (ob/ob) mouse models [7]. Jadoon et al. (2016) extended these findings to human subjects in a randomized, double-blind, placebo-controlled pilot trial of 62 patients with non-insulin-treated type 2 diabetes, in which THCV at 5 mg in the published literature for 13 weeks significantly decreased fasting plasma glucose, improved pancreatic beta-cell function (HOMA2), and increased adiponectin, without affecting appetite or body weight at the studied dose [8]. The neuroprotection application is supported by the Garcia et al. (2011) demonstration that THCV attenuates nigrostriatal neurodegeneration and motor inhibition in 6-hydroxydopamine rat models of Parkinson disease through combined antioxidant activity and CB2 receptor agonism [9]. A functional magnetic resonance imaging study in healthy volunteers (Rzepa et al., 2016) demonstrated that a single 10 mg oral dose of THCV reduces default mode network connectivity and increases executive control network connectivity, consistent with a procognitive or attention-enhancing central nervous system profile [10].

Pharmacokinetics following oral administration are characterized by a time to peak plasma concentration of approximately 3.8 to 5.0 hours, metabolism through pathways homologous to THC (principally 11-hydroxylation and subsequent carboxylation to 11-nor-9-carboxy-THCV), and dose-linear exposure over the range studied [11]. The compound is well tolerated in published human studies, with most adverse events rated mild and the most commonly reported event being euphoric mood at higher doses. THCV does not produce the anxiogenic, sedative, or appetite-stimulating effects characteristic of THC at doses studied in human trials.

This monograph reviews the chemistry, biosynthesis, and structural pharmacology of THCV; the multi-target receptor pharmacology including CB1, CB2, GPR55, 5-HT1A, and TRP channel interactions; the comprehensive pharmacokinetic record; the preclinical pharmacology across metabolic, neurodegenerative, anticonvulsant, and dermatologic models; the clinical evidence base in type 2 diabetes, neuroimaging, and safety; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications; adverse-event signal; and a structured comparative assessment of five cannabinoid receptor-targeting compounds against THCV on five competency standards. The compound is not approved by any regulatory authority as a medicine. It is available as a research-grade preparation and as a component of whole-plant Cannabis extracts; investigators should obtain analytical confirmation of identity, purity, and isomeric composition on every lot.